Decreased hippocampal 5-HT2A receptor binding in major depressive disorder: in vivo measurement with [18F]altanserin positron emission tomography
about
Frontolimbic Serotonin 2A Receptor Binding in Healthy Subjects Is Associated with Personality Risk Factors for Affective DisorderImaging the serotonin transporter during major depressive disorder and antidepressant treatmentMicrostructural abnormalities in subcortical reward circuitry of subjects with major depressive disorderSerotonergic modulation of suicidal behaviour: integrating preclinical data with clinical practice and psychotherapy.Molecular imaging for depressive disorders.Effects of serotonin-2A receptor binding and gender on personality traits and suicidal behavior in borderline personality disorder.5-HT radioligands for human brain imaging with PET and SPECTAltered expression of synapse and glutamate related genes in post-mortem hippocampus of depressed subjectsDecreased hippocampal 5-HT(2A) receptor binding in older depressed patients using [18F]altanserin positron emission tomography.G protein-coupled receptors in major psychiatric disorders.Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatmentTreatment of depressive-like behaviour in Huntington's disease mice by chronic sertraline and exercise.Sleep deprivation increases cerebral serotonin 2A receptor binding in humansSerotonin receptor subtype and p11 mRNA expression in stress-relevant brain regions of suicide and control subjectsMemory decline and depressive symptoms in a nationally representative sample of older adults: the Health and Retirement Study (1998-2004)Childhood adversity predicts earlier onset of major depression but not reduced hippocampal volume.A preclinical and clinical rationale for quetiapine in mood syndromes.Serotonin 5-HT(2A) Receptor Function as a Contributing Factor to Both Neuropsychiatric and Cardiovascular Diseases.Gender, personality, and serotonin-2A receptor binding in healthy subjectsMolecular imaging in patients with mood disorders: a review of PET findings.5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders.Functional anatomy of 5-HT2A receptors in the amygdala and hippocampal complex: relevance to memory functions.Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression.Neurobiological mechanisms of stress resilience and implications for the aged population.Gene expression related to serotonergic and glutamatergic neurotransmission is altered in the flinders sensitive line rat model of depression: Effect of ketamine.Serotonin transporter mRNA expression is decreased by lamivudine and ribavirin and increased by interferon in immune cells.Brain Arachidonic Acid Incorporation and Turnover are not Altered in the Flinders Sensitive Line Rat Model of Human Depression.'It's not over when it's over': persistent neurobiological abnormalities in recovered depressed patients.Interferon-alpha-induced serotonin uptake in Jurkat T cells via mitogen-activated protein kinase and transcriptional regulation of the serotonin transporter.Decreased brain serotonin 5-HT1A receptor availability in medication-naive patients with major depressive disorder: an in-vivo imaging study using PET and [carbonyl-11C]WAY-100635.5-HT2A receptor antagonism by MDL 11,939 during inescapable stress prevents subsequent exaggeration of acoustic startle response and reduced body weight in rats.Quantification of 5-HT1A and 5-HT2A Receptor Binding in Depressed Suicide Attempters and Non-Attempters.Different patterns of 5-HT receptor and transporter dysfunction in neuropsychiatric disorders--a comparative analysis of in vivo imaging findings.Region-specific regulation of the serotonin 2A receptor expression in development and ageing in post mortem human brain.Antidepressant-like effect of sodium butyrate (HDAC inhibitor) and its molecular mechanism of action in the rat hippocampus.Issues for DSM-V: I) including biological variables to objectively comfort the clinical diagnosis of borderline personality disorder and II) proposing a new subcategory to be included in the criteria sets for further study.5-HT2A: Its Role in Frontally Mediated Executive Function and Related Psychopathology
P2860
Q20984691-b8a3a167-4134-26a4-fa06-11685fc6516bQ24683135-BFC4B426-A861-444F-BA91-024A041F5B1AQ28744585-3DE8EE82-A915-42A6-9AA4-D7922DD57C79Q30663345-D32FF888-DBBF-43BC-A88F-25901E6975D6Q30821361-6E0BDF2A-6EC3-4DC2-852F-5AC2A6E560FFQ33970614-25473F55-0097-42B3-A488-6AB032E82408Q34192729-47DDB545-6826-4FF9-8620-E0DD6C72B781Q34254887-CFA3ED7C-E3A2-4C75-A12E-34A3D7711A2CQ34348375-8572ACB3-F85E-4B9B-AF82-0D0CF98B30B6Q34578414-D90FE0FA-D368-4265-A105-3FE16F44448DQ34661625-E168B09B-A6F5-4844-8FC3-B8111CF633B8Q36024880-CB362288-6D12-4A30-8251-E530411D109DQ36375242-EA8BD5C2-56D0-4C23-B9C2-4B2C287C0A66Q36491567-D854FFF3-7349-4E5F-A6A8-85E8ED2F8E8BQ36538293-BC810F13-A5DE-4A66-8404-28A2B51B222DQ36656403-9B12E7F8-FF1A-4E56-AEAD-46398DC164DEQ36847279-A1D85CF1-778C-4A13-9E7B-297384C90231Q37464848-0102D904-8DC9-43A2-8AB7-B9A77106AAE2Q37480664-421A9082-55E2-43D8-8320-695BB3D4DCCCQ37864156-6F4B925B-4A37-4FBF-87EA-B36E83EB797BQ38081485-3640345E-562C-4EBA-B6B1-A4F222AE92E1Q38099540-BCB9D37E-246A-42FE-93F2-834551C22920Q39067664-58847585-E4CA-4A9C-8C47-F7F2B8DB9EF0Q39311440-F17C97D4-278D-4DD5-A5B7-C19BD9852675Q39427905-57C2F4D2-C9E5-4170-92A8-D85604B58599Q40316854-E46D4DC8-DDBF-42B8-B06D-9883BE34F227Q46037434-DFFF55DB-075C-471D-AF5B-8A528E1B6335Q46621019-903456C6-BA2B-4C6E-A716-EB88119057B5Q46727007-96978798-482F-4A9F-8C7C-B1A0112F3920Q46923228-FA89842C-F799-483B-9911-495E518F6681Q47587514-16E78E8D-0B3E-4C02-8B6E-D5DA72206AADQ47667959-CFB40AE7-D07E-4526-92E3-F3A61E029AA6Q48074706-AFBCFBFC-679E-4072-88F1-B7C5838A5DA3Q48251072-50774941-EFE0-4079-B30E-7E9F6EAA4549Q48818809-605F6A01-3F73-46BF-9339-7AD2D667B308Q51870331-1E85C785-25FC-4D90-97DD-FB18D8DF17D0Q57569733-9DF6C72D-1DEE-445C-80F6-6ABFF01E8E16
P2860
Decreased hippocampal 5-HT2A receptor binding in major depressive disorder: in vivo measurement with [18F]altanserin positron emission tomography
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Decreased hippocampal 5-HT2A r ...... n positron emission tomography
@ast
Decreased hippocampal 5-HT2A r ...... n positron emission tomography
@en
Decreased hippocampal 5-HT2A r ...... n positron emission tomography
@nl
type
label
Decreased hippocampal 5-HT2A r ...... n positron emission tomography
@ast
Decreased hippocampal 5-HT2A r ...... n positron emission tomography
@en
Decreased hippocampal 5-HT2A r ...... n positron emission tomography
@nl
prefLabel
Decreased hippocampal 5-HT2A r ...... n positron emission tomography
@ast
Decreased hippocampal 5-HT2A r ...... n positron emission tomography
@en
Decreased hippocampal 5-HT2A r ...... n positron emission tomography
@nl
P2093
P50
P1476
Decreased hippocampal 5-HT2A r ...... n positron emission tomography
@en
P2093
Andrei G Vlassenko
Stephen M Moerlein
Yiyun Huang
P304
P356
10.1016/J.BIOPSYCH.2003.08.015
P407
P577
2004-02-01T00:00:00Z